Timothy Goodson, MD
Urology · Little Rock, ARNPI 1578538252
Payments from drug & device makers
Across 604 payments — averaging $243.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cryo Specialty Medical, LLC$125K
- Astellas Pharma US Inc$3K
- AbbVie$3K
- Pfizer$3K
- Coloplast$3K
- Astellas Pharma Global Development$2K
- plus $9K from 30 others
What the payments were for
- Consulting fees$3,9203%
- Speaking & faculty fees$18,32512%
- Travel & lodging$8261%
- Food & beverage$13,0719%
- Education$1360%
- Ownership interest$111,00075%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cryo Specialty Medical, LLC | 11 | $124,500 |
| Astellas Pharma US Inc | 63 | $3,395 |
| AbbVie(2 entities) | 38 | $3,131 |
| Pfizer | 32 | $2,825 |
| Coloplast | 138 | $2,685 |
| Astellas Pharma Global Development | 1 | $1,920 |
| Axonics, Inc. | 50 | $1,269 |
| Myriad Genetic Laboratories, Inc. | 19 | $1,135 |
| Sumitomo Pharma America, Inc. | 48 | $940 |
| Teleflex LLC | 12 | $794 |
| Johnson & Johnson | 31 | $794 |
| Dendreon Pharmaceuticals LLC | 21 | $658 |
| Boston Scientific | 13 | $561 |
| Neotract Inc. | 9 | $365 |
| Myovant Sciences Inc. | 11 | $278 |
| Blue Earth Diagnostics | 13 | $253 |
| Bayer | 13 | $241 |
| Novartis | 11 | $211 |
| Verity Pharmaceuticals Inc. | 7 | $169 |
| Medtronic(2 entities) | 16 | $157 |
| Tolmar, Inc. | 8 | $150 |
| Procept Biorobotics Corporation | 5 | $127 |
| AstraZeneca | 5 | $110 |
| Ferring Pharmaceuticals Inc. | 5 | $102 |
| Antares Pharma, Inc. | 5 | $98 |
| Urogen Pharma, Inc. | 3 | $81 |
| Amgen | 3 | $63 |
| Olympus America Inc. | 2 | $52 |
| Angiodynamics, Inc. | 2 | $42 |
| Merck | 2 | $37 |
| Urovant Sciences Inc | 2 | $31 |
| Photocure Inc | 1 | $31 |
| Valencia Technologies Corporation | 1 | $24 |
| Tolmar Pharmaceuticals, Inc. | 1 | $24 |
| Travere Therapeutics, Inc. | 1 | $14 |
| Caris MPI, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$147,278 in reported general payments places this provider in the 95th percentile of 88 urology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 38 | $540,495 |
| XtandiEnzalutamide | 38 | $533,358 |
| NubeqaDarolutamide | 31 | $406,343 |
| MyrbetriqMirabegron | 231 | $139,533 |
| GemtesaVibegron | 170 | $107,050 |
| OrgovyxRelugolix | 23 | $59,219 |
| ElmironPentosan Polysulfate Sodium | 39 | $29,965 |
| Tamsulosin Hcl | 1,146 | $13,955 |
| Oxybutynin Chloride ErOxybutynin Chloride | 539 | $8,934 |
| Finasteride | 725 | $7,617 |
| Trimethoprim | 123 | $6,303 |
| Estradiol | 38 | $2,427 |
| Dutasteride | 49 | $1,523 |
| Potassium Citrate ErPotassium Citrate | 44 | $1,318 |
| Ciprofloxacin Hcl | 268 | $1,233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $3,395 | $672,891269 claims |
| Johnson & JohnsonErleada | $794 | $540,49538 claims |
| BayerNubeqa | $241 | $406,34331 claims |
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $940 | $166,269193 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 88 urology providers in Arkansas.
Other urology in Little Rock
- Richard D AnnaLittle Rock$737K
- Donald MooneyLittle Rock$562K
- Timothy LangfordLittle Rock$180K
- Caleb BozemanLittle Rock$136K
- David CoussensLittle Rock$134K
- Kevin ClaybrookLittle Rock$132K
- John MooreLittle Rock$128K
- Gail JonesLittle Rock$128K
- Michael ChildsLittle Rock$8K
- Bruno Lopes Cancado MachadoLittle Rock$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.